Calidi Biotherapeutics Statistics
Total Valuation
CLDI has a market cap or net worth of $6.20 million. The enterprise value is $4.89 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, after market close.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDI has 3.88 million shares outstanding. The number of shares has increased by 138.25% in one year.
| Current Share Class | 3.73M |
| Shares Outstanding | 3.88M |
| Shares Change (YoY) | +138.25% |
| Shares Change (QoQ) | -69.47% |
| Owned by Insiders (%) | 8.59% |
| Owned by Institutions (%) | 6.17% |
| Float | 2.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.63 |
| P/TBV Ratio | 3.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 1.93.
| Current Ratio | 1.13 |
| Quick Ratio | 1.00 |
| Debt / Equity | 1.93 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -37.62 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -158.23% |
| Return on Invested Capital (ROIC) | -813.70% |
| Return on Capital Employed (ROCE) | -499.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$828,357 |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLDI has paid $9,000 in taxes.
| Income Tax | 9,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.51% in the last 52 weeks. The beta is 1.08, so CLDI's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -88.51% |
| 50-Day Moving Average | 4.90 |
| 200-Day Moving Average | 8.71 |
| Relative Strength Index (RSI) | 30.65 |
| Average Volume (20 Days) | 474,202 |
Short Selling Information
The latest short interest is 377,501, so 9.74% of the outstanding shares have been sold short.
| Short Interest | 377,501 |
| Short Previous Month | 650,514 |
| Short % of Shares Out | 9.74% |
| Short % of Float | 14.17% |
| Short Ratio (days to cover) | 0.36 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.98M |
| Pretax Income | -29.96M |
| Net Income | -23.19M |
| EBITDA | -19.53M |
| EBIT | -19.98M |
| Earnings Per Share (EPS) | -$33.66 |
Full Income StatementBalance Sheet
The company has $5.28 million in cash and $4.01 million in debt, giving a net cash position of $1.27 million or $0.33 per share.
| Cash & Cash Equivalents | 5.28M |
| Total Debt | 4.01M |
| Net Cash | 1.27M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 2.08M |
| Book Value Per Share | 2.56 |
| Working Capital | 696,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.38 million and capital expenditures -$75,000, giving a free cash flow of -$22.46 million.
| Operating Cash Flow | -22.38M |
| Capital Expenditures | -75,000 |
| Free Cash Flow | -22.46M |
| FCF Per Share | -$5.79 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
